Pulling SEC filings + quote and writing the call…
SNDX
Syndax Pharmaceuticals Inc
Next earnings Aug 3, 2026 · consensus $-0.49 EPS, $80.9M rev
Last earnings +3.9% on 2026-04-30
$19.36
▲ +1.87%$19.00▲ +90.19%
over 1Y
L $8.73EODHDH $25.15
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.9%
1W+6.1%
1M-1.9%
3M-20.8%
YTD-10.8%
1Y+90.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Strong Buy
Revenue grew 627.8% YoY; but unprofitable (net margin -165.6%).
Syndax Pharmaceuticals Inc shows $172M in FY2025 revenue (+627.8% YoY), a -165.6% net margin, and -441.6% ROE.
Sources: SEC EDGAR (CIK 0001395937, latest 10-Q filed 2026-04-30) · EODHD · as of 6/22/2026, 5:48:49 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.